# Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer

> **NCT03085992** · PHASE2 · COMPLETED · sponsor: **Azienda Ospedaliero, Universitaria Pisana** · enrollment: 49 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** FOLFOXIRI plus Bevacizumab
- **OTHER:** Chemoradiotherapy plus Bevacizumab

## Key facts

- **NCT ID:** NCT03085992
- **Lead sponsor:** Azienda Ospedaliero, Universitaria Pisana
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2017-07
- **Final completion:** 2018-03-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2018-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03085992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03085992, "Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03085992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*